TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EVE Health Group Limited ( (AU:EVE) ) has shared an announcement.
EVE Health Group Limited has announced the launch of two innovative products: Dyspro, a fast-acting non-hormonal gummy for menstrual pain, and Libbo, a rapid-onset oral strip for erectile dysfunction. These products target the large, underserved global markets for dysmenorrhoea and erectile dysfunction, valued at US$10.92 billion and US$5.31 billion respectively. The company’s patent-pending nano-emulsion technology enhances the speed and effectiveness of these formulations. Dyspro has already been launched in Australia, with Libbo expected to follow in December, marking a significant step in the company’s commercialisation efforts.
More about EVE Health Group Limited
EVE Health Group Limited is an emerging pharmaceutical company specializing in innovative drug delivery technology. The company focuses on the women’s health market, with a pipeline that includes solutions for men’s health as well.
Average Trading Volume: 653,718
Technical Sentiment Signal: Sell
Current Market Cap: A$7.35M
For an in-depth examination of EVE stock, go to TipRanks’ Overview page.